ABCSG C09/ASAMET Summary

Randomized, phase II, double-blind, placebo-controlled, multicenter, 2×2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in stage I-III colorectal cancer patients.

Start:

04/2017 (international), 10/2018 (national)

Coordinating Investigator:

Gnant, Michael; Wien

Sample size:

160 (international)

Design:
(Click to enlarge)

ABCSG C09/ASAMET